Chongqing Lummy Pharmaceutical Co., Ltd. (300006.SZ)
CNY 5.25
(-2.42%)
CNY 5.25
(-2.42%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -56.7 Million CNY | -12.72% |
| 2022 | -96.03 Million CNY | -36.92% |
| 2021 | -70.14 Million CNY | 79.73% |
| 2020 | -346.09 Million CNY | -104.87% |
| 2019 | -168.93 Million CNY | -254.28% |
| 2018 | 109.49 Million CNY | 126.7% |
| 2017 | 48.3 Million CNY | 1331.95% |
| 2016 | -3.92 Million CNY | -123.72% |
| 2015 | 16.52 Million CNY | 248.49% |
| 2014 | 4.74 Million CNY | -90.48% |
| 2013 | 49.82 Million CNY | -6.79% |
| 2012 | 53.45 Million CNY | -19.05% |
| 2011 | 66.03 Million CNY | 38.9% |
| 2010 | 47.54 Million CNY | 5.5% |
| 2009 | 45.06 Million CNY | 28.11% |
| 2008 | 35.17 Million CNY | 19.0% |
| 2007 | 29.56 Million CNY | 231.06% |
| 2006 | 8.92 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -25.68 Million CNY | -1520.77% |
| 2024 Q3 | -27.43 Million CNY | -6.79% |
| 2024 Q1 | 1.8 Million CNY | 104.63% |
| 2023 Q3 | 1.65 Million CNY | 114.78% |
| 2023 Q4 | -39.01 Million CNY | -2453.65% |
| 2023 Q2 | -11.21 Million CNY | -246.75% |
| 2023 FY | -108.25 Million CNY | -12.72% |
| 2023 Q1 | -3.23 Million CNY | 88.86% |
| 2022 Q1 | -27.78 Million CNY | 71.02% |
| 2022 Q2 | -32.87 Million CNY | -18.32% |
| 2022 Q3 | -6.34 Million CNY | 80.7% |
| 2022 Q4 | -29.03 Million CNY | -357.68% |
| 2022 FY | -96.03 Million CNY | -36.92% |
| 2021 Q4 | -95.85 Million CNY | -608.99% |
| 2021 FY | -70.14 Million CNY | 79.73% |
| 2021 Q2 | -23.77 Million CNY | -137.73% |
| 2021 Q3 | -13.52 Million CNY | 43.13% |
| 2021 Q1 | 63.01 Million CNY | 117.57% |
| 2020 Q2 | 16.78 Million CNY | 230.03% |
| 2020 Q4 | -358.61 Million CNY | -4247.69% |
| 2020 Q1 | -12.9 Million CNY | 94.87% |
| 2020 FY | -346.09 Million CNY | -104.87% |
| 2020 Q3 | 8.64 Million CNY | -48.48% |
| 2019 Q3 | 15.99 Million CNY | -61.71% |
| 2019 FY | -168.93 Million CNY | -254.28% |
| 2019 Q1 | 24.98 Million CNY | 1163.84% |
| 2019 Q2 | 41.77 Million CNY | 67.18% |
| 2019 Q4 | -251.68 Million CNY | -1673.52% |
| 2018 FY | 109.49 Million CNY | 126.7% |
| 2018 Q4 | 1.97 Million CNY | -88.15% |
| 2018 Q3 | 16.67 Million CNY | -60.97% |
| 2018 Q2 | 42.73 Million CNY | -11.18% |
| 2018 Q1 | 48.11 Million CNY | 414.38% |
| 2017 Q1 | 20.81 Million CNY | 131.33% |
| 2017 Q3 | 20.39 Million CNY | -8.9% |
| 2017 FY | 48.3 Million CNY | 1331.95% |
| 2017 Q4 | -15.3 Million CNY | -175.02% |
| 2017 Q2 | 22.39 Million CNY | 7.6% |
| 2016 FY | -3.92 Million CNY | -123.72% |
| 2016 Q1 | 25.38 Million CNY | 316.12% |
| 2016 Q2 | 14.88 Million CNY | -41.36% |
| 2016 Q3 | 22.24 Million CNY | 49.46% |
| 2016 Q4 | -66.43 Million CNY | -398.63% |
| 2015 Q2 | 5.94 Million CNY | 27.52% |
| 2015 Q1 | 4.66 Million CNY | -80.78% |
| 2015 Q3 | -186.31 Thousand CNY | -103.13% |
| 2015 FY | 16.52 Million CNY | 248.49% |
| 2015 Q4 | 6.09 Million CNY | 3373.8% |
| 2014 Q3 | 8.56 Million CNY | 222.03% |
| 2014 Q4 | 24.26 Million CNY | 183.25% |
| 2014 Q2 | -7.01 Million CNY | 66.68% |
| 2014 Q1 | -21.06 Million CNY | -202.06% |
| 2014 FY | 4.74 Million CNY | -90.48% |
| 2013 Q4 | 20.64 Million CNY | 154.75% |
| 2013 Q3 | 8.1 Million CNY | -46.97% |
| 2013 Q2 | 15.28 Million CNY | 163.48% |
| 2013 Q1 | 5.8 Million CNY | 49.15% |
| 2013 FY | 49.82 Million CNY | -6.79% |
| 2012 FY | 53.45 Million CNY | -19.05% |
| 2012 Q3 | 14.44 Million CNY | -9.8% |
| 2012 Q2 | 16.01 Million CNY | -16.22% |
| 2012 Q4 | 3.88 Million CNY | -73.08% |
| 2012 Q1 | 19.11 Million CNY | 38.48% |
| 2011 Q2 | 16.85 Million CNY | -17.01% |
| 2011 FY | 66.03 Million CNY | 38.9% |
| 2011 Q1 | 20.31 Million CNY | 29.8% |
| 2011 Q4 | 13.8 Million CNY | -8.37% |
| 2011 Q3 | 15.06 Million CNY | -10.65% |
| 2010 Q1 | 12.44 Million CNY | -4.43% |
| 2010 Q3 | 8.87 Million CNY | -15.99% |
| 2010 Q4 | 15.65 Million CNY | 76.25% |
| 2010 FY | 47.54 Million CNY | 5.5% |
| 2010 Q2 | 10.57 Million CNY | -15.06% |
| 2009 FY | 45.06 Million CNY | 28.11% |
| 2009 Q4 | 13.02 Million CNY | 22.6% |
| 2009 Q3 | 10.62 Million CNY | 12.58% |
| 2009 Q2 | 9.43 Million CNY | -21.34% |
| 2009 Q1 | 11.99 Million CNY | 6.13% |
| 2008 FY | 35.17 Million CNY | 19.0% |
| 2008 Q4 | 11.3 Million CNY | 26.24% |
| 2008 Q3 | 8.95 Million CNY | 0.0% |
| 2007 FY | 29.56 Million CNY | 231.06% |
| 2006 FY | 8.92 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Zhejiang Int'l Group Co.,Ltd. | 825.98 Million CNY | 106.865% |
| Zhejiang Zhenyuan Share Co., Ltd. | 113.04 Million CNY | 150.165% |
| Hunan Jingfeng Pharmaceutical Co.,Ltd. | -104.37 Million CNY | 45.673% |
| Hubei Guangji Pharmaceutical Co., Ltd. | -141.05 Million CNY | 59.798% |
| Yifan Pharmaceutical Co., Ltd. | -882.71 Million CNY | 93.576% |
| Guangdong Jiaying Pharmaceutical Co., Ltd | 40.51 Million CNY | 239.963% |
| Sichuan Kelun Pharmaceutical Co., Ltd. | 3.65 Billion CNY | 101.552% |
| Boai NKY Medical Holdings Ltd. | 585.23 Million CNY | 109.69% |
| Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. | 344.97 Million CNY | 116.438% |